Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,652 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Regeneron Pharmaceuticals were worth $21,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of REGN. Private Advisor Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.0% during the 3rd quarter. Private Advisor Group LLC now owns 5,361 shares of the biopharmaceutical company’s stock worth $5,635,000 after acquiring an additional 303 shares during the last quarter. Silver Oak Securities Incorporated boosted its stake in shares of Regeneron Pharmaceuticals by 523.5% during the 3rd quarter. Silver Oak Securities Incorporated now owns 929 shares of the biopharmaceutical company’s stock worth $969,000 after acquiring an additional 780 shares during the last quarter. Ballentine Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.9% during the 3rd quarter. Ballentine Partners LLC now owns 1,062 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 50 shares during the last quarter. Elwood & Goetz Wealth Advisory Group LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $517,000. Finally, Allworth Financial LP boosted its stake in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. Allworth Financial LP now owns 709 shares of the biopharmaceutical company’s stock worth $745,000 after acquiring an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Bank of America restated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $700.33 on Friday. The firm’s fifty day simple moving average is $699.40 and its two-hundred day simple moving average is $882.47. The company has a market cap of $76.56 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 2.34 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the business earned $11.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.